The bill amends K.S.A. 2024 Supp. 65-4101 and K.S.A. 2024 Supp. 65-4111 to update definitions and classifications related to controlled substances in Kansas. It revises the definition of "administer" to allow patients or research subjects to apply controlled substances under the direction and in the presence of a practitioner, removing the previous requirement for the practitioner to be the only one present. The term "medical care facility" is also clarified to align with the existing definition in K.S.A. 65-425. Additionally, the bill introduces new definitions for "electronic prescription," "electronic signature," and "intermediary," which are crucial for modernizing the prescription process, and includes a detailed list of substances classified under schedule IV.

Moreover, the bill addresses the regulation of crystalline polymorph psilocybin, stipulating that once the FDA approves a pharmaceutical composition of this substance, the Attorney General must certify the approval to the Secretary of State within seven days, who will then publish it in the Kansas Register. The bill also repeals existing laws related to psilocybin upon its publication, thereby updating the legal framework surrounding this substance. Overall, the amendments aim to enhance the regulation of controlled substances in Kansas, ensuring compliance with current federal regulations and improving the legal framework for the administration and distribution of these substances. The act will take effect immediately upon its publication in the statute book.

Statutes affected:
As introduced: 65-4101, 65-4111